L04 RD1
Alternative Names: L 04 RD 1Latest Information Update: 23 Aug 2023
Price :
$50 *
At a glance
- Originator Celltrion
- Class Antihypertensives; Cardiovascular therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Essential hypertension
Most Recent Events
- 29 Jun 2023 Celltrion completes a phase I trial in Essential hypertension (In volunteers) in South Korea (NCT05993806)
- 02 Jun 2023 Celltrion initiates a phase I trial in Essential hypertension (In volunteers) in South Korea (NCT05993806)
- 29 Nov 2022 Celltrion completes a phase I trial (In volunteers) in South Korea (PO) (NCT05581693)